A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.

Georg A. Bjarnason, J. A. Miller, Jennifer J. Knox et al.|Journal of Clinical Oncology|2013

Cited by 5